Aflibercept
Treatment for Macular Degeneration
Typical Dosage: 2 mg intravitreal injection every 4 weeks for 3 months, then every 8 weeks
Effectiveness
90%
Safety Score
45%
Clinical Trials
280
Participants
50K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
45
DangerousModerateSafe
Treatment Details
Dosage Range
2 mg intravitreal injection every 4 weeks for 3 months, then every 8 weeks
Time to Effect
1-2 weeks
Treatment Duration
lifetime
Evidence Quality
HIGHConfidence Score
98%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$12,000
Monitoring:$750
Side Effect Mgmt:$300
Total Annual:$13,050
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$80,000/QALY
QALYs Gained
0.85
Outcome-Based Costs
Cost per Responder
$14,032.26
Comparison vs Bevacizumab
Cost Difference
+$11,200/year
More expensive
QALY Difference
0.00 QALYs
Same outcomes
Dominance
No dominance
Aflibercept Outcomes
for Macular Degeneration
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+93%
Common Side Effects
Conjunctival hemorrhage
+15%
Eye pain
+8%
Vitreous floaters
+7%
Increased intraocular pressure
+3%
Endophthalmitis
+0.05%
Retinal detachment
+0.05%
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
17 completed trials for Aflibercept in Macular Degeneration
Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)
NCT00320788COMPLETEDPHASE2
159 participants
INTERVENTIONAL
Phoenix, United States +17 more
Started: Apr 1, 2006
Randomized, Single-Masked, Long-Term, Safety and Tolerability Study of VEGF Trap-Eye in AMD
NCT00527423COMPLETEDPHASE2
157 participants
INTERVENTIONAL
Peoria, United States +32 more
Started: Aug 1, 2007
Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to Aflibercept
NCT01617148COMPLETEDPHASE4
26 participants
INTERVENTIONAL
Cleveland, United States
Started: Jun 1, 2012
Pharmacokinetic Study of Intravitreal Aflibercept Injection in Eyes With Wet Age-related Macular Degeneration
NCT02204683COMPLETEDPHASE1
5 participants
INTERVENTIONAL
Omaha, United States
Started: Sep 5, 2014
Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD
NCT00320775COMPLETEDPHASE1
51 participants
INTERVENTIONAL
Tuscon, United States +7 more
Started: Jun 1, 2005
EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection
NCT02689518COMPLETEDPHASE4
50 participants
INTERVENTIONAL
La Jolla, United States
Started: Apr 1, 2014
Aflibercept Injection Into the Vitreous Body of the Eye: Study to Learn More About Patient Relevant Outcomes, Real World Treatment Patterns and How Well the Treatment Works for Patients Suffering From Abnormal Growth of New Blood Vessels Under the Retina.
NCT03714308COMPLETED
554 participants
OBSERVATIONAL
Multiple Locations, Germany
Started: Jan 28, 2019
Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
NCT02540954COMPLETEDPHASE3
336 participants
INTERVENTIONAL
Vienna, Austria +70 more
Started: Sep 29, 2015
VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration)
NCT01482910COMPLETEDPHASE3
304 participants
INTERVENTIONAL
Guangzhou, China +13 more
Started: Dec 1, 2011
Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)
NCT00509795COMPLETEDPHASE3
1.22K participants
INTERVENTIONAL
Birmingham, United States +187 more
Started: Aug 1, 2007
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)
NCT00637377COMPLETEDPHASE3
1.24K participants
INTERVENTIONAL
Buenos Aires, Argentina +188 more
Started: Apr 1, 2008
Evaluate the Effectiveness of Intravitreal (IVT) Aflibercept Injection in Clinical Practice in naïve Patients With Neovascular Age-related Macular Degeneration (nAMD)
NCT03411941COMPLETED
116 participants
OBSERVATIONAL
Multiple Locations, Spain
Started: Feb 28, 2018
Ziv-aflibercept Efficacy in Better Regulating AMD
NCT03423823COMPLETEDPHASE2
62 participants
INTERVENTIONAL
Virginia Beach, United States
Started: Jul 7, 2017
EYLEA Age-Related Macular Degeneration (AMD) Post-marketing Surveillance in Japan
NCT01756248COMPLETED
3.87K participants
OBSERVATIONAL
Multiple Locations, Japan
Started: Dec 26, 2012
A Study in Patients With Wet Age-related Macular Degeneration or Diabetic Macular Edema to Assess the freQuency of Use of Intravitreal Aflibercept in Routine Clinical Practices in Latin America
NCT03470103COMPLETED
643 participants
OBSERVATIONAL
Multiple Locations, Argentina +3 more
Started: Mar 28, 2018
EYLEA [AMD-QOL(Age-Related Macular Degeneration-Quality of Life)] Post-marketing Surveillance in Japan
NCT01756261COMPLETED
757 participants
OBSERVATIONAL
Multiple Locations, Japan
Started: Dec 26, 2012
Study to Evaluate Efficacy of Aflibercept in Neovascular Age-related Macular Degeneration Patients Non Responders to Anti-Vascular Endothelial Growth Factor
NCT01896284COMPLETEDPHASE4
46 participants
INTERVENTIONAL
Barcelona, Spain
Started: Jul 1, 2013
Showing 20 of 282 total trials